Cargando…
Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil
Background: Conventional synthetic disease-modifying antirheumatic drugs are the first-line treatment to inhibit the progression of psoriatic arthritis. Despite their widespread clinical use, few studies have been conducted to compare these drugs for psoriatic arthritis. Methods: a longitudinal stud...
Autores principales: | Faria, Ronaldo José, Cordeiro, Francisca Janiclecia Rezende, dos Santos, Jéssica Barreto Ribeiro, Alvares-Teodoro, Juliana, Guerra Júnior, Augusto Afonso, Acurcio, Francisco de Assis, da Silva, Michael Ruberson Ribeiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086188/ https://www.ncbi.nlm.nih.gov/pubmed/35559237 http://dx.doi.org/10.3389/fphar.2022.878972 |
Ejemplares similares
-
Medication persistence for psoriatic arthritis in a Brazilian real-world setting
por: Ribeiro da Silva, Michael Ruberson, et al.
Publicado: (2019) -
Functionality assessment in patients with rheumatic diseases undergoing treatment in the Public Health System
por: de Souza, Elisa Neide Barbosa, et al.
Publicado: (2022) -
First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study
por: da Silva, Michael Ruberson Ribeiro, et al.
Publicado: (2022) -
Self-Medication during the COVID-19 Pandemic in Brazil: Findings and Implications to Promote the Rational Use of Medicines
por: Bazoni, Patrícia Silva, et al.
Publicado: (2023) -
Who should pay for the continuity of post-trial health care treatments?
por: Iunes, Roberto, et al.
Publicado: (2019)